Dose escalation and cohort expansion safety study of intrathecal trastuzumab in patients with HER2 positive parenchymal brain metastatic breast cancer

Trial Profile

Dose escalation and cohort expansion safety study of intrathecal trastuzumab in patients with HER2 positive parenchymal brain metastatic breast cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2015

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top